Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone

S. Salvi, V. Casadio, V. Conteduca, S. L. Burgio, C. Menna, E. Bianchi, L. Rossi, E. Carretta, C. Masini, D. Amadori, D. Calistri, G. Attard, U. De Giorgi

Research output: Contribution to journalArticle


Background:This study aimed to investigate copy number variations (CNVs) of CYP17A1 and androgen receptor (AR) genes in serum cell-free DNA collected before starting abiraterone in 53 consecutive patients with castration-resistant prostate cancer (CRPC).Methods:Serum DNA was isolated and CNVs were analysed for AR and CYP17A1 genes using Taqman copy number assays. The association between CNVs and progression-free/overall survival (PFS/OS) was evaluated by the Kaplan-Meier method and log-rank test.Results:Median PFS of patients with AR gene gain was 2.8 vs 9.5 months of non-gained cases (P

Original languageEnglish
Pages (from-to)1717-1724
Number of pages8
JournalBritish Journal of Cancer
Issue number10
Publication statusPublished - May 12 2015



  • abiraterone
  • androgen receptor
  • castration-resistant prostate cancer
  • circulating cell-free DNA
  • CYP17A1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this